Why Pfizer's Post-COVID Future Looks Brighter Than Ever
It's been a rough few years to be a (NYSE: PFE) shareholder. Shares of the big pharma stock are down about 61% from a peak they set in late 2021. That year, the company's COVID-19 vaccine, Comirnaty, racked up $36.8 billion in sales.
In the first half of 2025, Comirnaty sales came in at just $945 million. Sales of Paxlovid, an antiviral treatment for COVID-19, fell 60% year over year to $918 million. Despite sinking demand for Comirnaty and Paxlovid, Pfizer's post-COVID future looks bright.
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Aktie
23,56 €
1,68 %
Die Pfizer Inc. Aktie erhält eine Reihe von Buy-Einschätzungen, die die Sell-Zahlen übertreffen.
Das von der Community festgelegte Kursziel von 29 € für Pfizer Inc. bedeutet eine mögliche Steigerung um über 20% im Vergleich zu 23.56 €.
